Full Text View
Tabular View
No Study Results Posted
Related Studies
Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults
This study has suspended participant recruitment.
( Preserve clinical supplies for optimized dosing regimen )
Study NCT00995540   Information provided by Exsulin Corporation

First Received on October 13, 2009.   Last Updated on December 10, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 1 Diabetes Mellitus
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 1
More general conditions related to this trial
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Interventions listed in this trial
INGAP Peptide
Placebo
Sponsors listed in this trial
Exsulin Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services